NCT07030400 Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
| NCT ID | NCT07030400 |
| Status | Recruiting |
| Phase | — |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Condition | Small Lymphocytic Lymphoma (SLL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-07-17 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-07-17 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.
Eligibility Criteria
Inclusion Criteria: * All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included. * Subjects must be able to read and speak English or Spanish at the 8th grade level. Exclusion Criteria: * Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.
Contact & Investigator
Sara Tinsley-Vance, PhD, APRN, AOCN
PRINCIPAL INVESTIGATOR
Moffitt Cancer Center
Frequently Asked Questions
Who can join the NCT07030400 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Small Lymphocytic Lymphoma (SLL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07030400 currently recruiting?
Yes, NCT07030400 is actively recruiting participants. Contact the research team at Daniel.Lastorino@moffitt.org for enrollment information.
Where is the NCT07030400 trial being conducted?
This trial is being conducted at Tampa, United States.
Who is sponsoring the NCT07030400 clinical trial?
NCT07030400 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Sara Tinsley-Vance, PhD, APRN, AOCN at Moffitt Cancer Center. The trial plans to enroll 100 participants.